Anzahl der Publikationen: 3
Zeitschriftenartikel
Bernhardt, Alexander M.
ORCID: https://orcid.org/0000-0002-2572-5062; Longen, Sebastian; Trossbach, Svenja V.; Rossi, Marcello; Weckbecker, Daniel; Schmidt, Felix; Jäck, Alexander; Katzdobler, Sabrina
ORCID: https://orcid.org/0000-0002-3512-5984; Fietzek, Urban M.; Weidinger, Endy; Palleis, Carla
ORCID: https://orcid.org/0000-0002-4331-8145; Ruf, Viktoria; Baiardi, Simone; Parchi, Piero; Höglinger, Günter U.
ORCID: https://orcid.org/0000-0001-7587-6187; Matthias, Torsten; Levin, Johannes
ORCID: https://orcid.org/0000-0001-5092-4306 und Giese, Armin
(2025):
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.
In: Acta Neuropathologica, Bd. 149, 20
[PDF, 1MB]
Bernhardt, Alexander Maximilian
ORCID: https://orcid.org/0000-0002-2572-5062; Rodríguez‐Baz, Íñigo
ORCID: https://orcid.org/0000-0003-3039-9115; Aldecoa, Iban; Arranz, Javier; Arriola‐Infante, José Enrique; Maure‐Blesa, Lucia; Carmona‐Iragui, Maria; Longen, Sebastian; Trossbach, Svenja Verena; Giese, Armin; Matthias, Torsten; Benejam, Bessy; Videla, Laura; del Hoyo Soriano, Laura; Barroeta, Isabel; Sanjuan, Aída; Fernández, Susana; Vaqué‐Alcázar, Lídia; Rozalem Aranha, Mateus; Morcillo‐Nieto, Alejandra O.; Nübling, Georg; Wagemann, Olivia; Stockbauer, Anna; Tondo, Mireia; Bejanin, Alexandre; Lleó, Alberto; Alcolea, Daniel; Molina‐Porcel, Laura; Fortea, Juan und Levin, Johannes
ORCID: https://orcid.org/0000-0001-5092-4306
(2025):
Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease.
In: Alzheimer's & Dementia, Bd. 21, Nr. 6, e70342
[PDF, 1MB]
Levin, Johannes; Sing, Nand; Melbourne, Sue; Morgan, Amber; Mariner, Carla; Spillantini, Maria Grazia; Wegrzynowicz, Michal; Dalley, Jeffrey W.; Langer, Simon; Ryazanov, Sergey; Leonov, Andrei; Griesinger, Christian; Schmidt, Felix; Weckbecker, Daniel; Prager, Kai; Matthias, Torsten und Giese, Armin
(2022):
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind placebo-controlled phase 1a trial.
In: eBioMedicine, Bd. 80, 104021
[PDF, 612kB]
Diese Liste wurde am
Sun Nov 30 00:32:30 2025 CET
erstellt.